How PhaseFolio values a drug asset
The valuation framework behind every signed export: the rNPV model, the reference data it starts from, the assumptions PhaseFolio makes and how each one can be changed. These chapters document the Workspace valuation model. Atlas documents its source coverage and retrieval methods separately.
Limits of use
The figures here are reference data from published sources and assumptions PhaseFolio labels as its own. The model has not been backtested, its outputs are not predictions for any asset, and nothing here is investment, legal, tax or medical advice. Every value can be changed, and the model computes with the values you keep.
DModel card and version history
The section pages describe the current release one part at a time. The model card is the long-form record of the whole release: what the model is for and not for, where every default comes from, the assumptions PhaseFolio makes, what we found while building it and what has not been tested. A new edition is published with each methodology release.
Every release stays citable. Earlier versions of each section remain available, and the version history lists what changed and why.
ESources and citations
Each section lists its own references, with DOI links for journal articles and official pages for reports, filings and statute. Where a figure is a PhaseFolio assumption rather than a published value, the section says so beside it.